tiprankstipranks
Apogee Therapeutics, Inc. (APGE)
NASDAQ:APGE
US Market
APGE
Apogee Therapeutics
RESEARCH TOOLSreports
Want to see APGE full AI Analyst Report?

Apogee Therapeutics (APGE) Stock News & Sentiment

361 Followers
Michael Yee Reaffirms Buy on Apogee, Citing Differentiated Zumilokibart Profile, Upcoming Data Catalysts, and Maintained $100 Price Target
Premium
Ratings
Michael Yee Reaffirms Buy on Apogee, Citing Differentiated Zumilokibart Profile, Upcoming Data Catalysts, and Maintained $100 Price Target
11d ago
APGE
Analyst Reiterates Buy on Apogee, Maintains $137 Price Target on Strong Zumilokibart Profile and Pipeline Upside
Premium
Ratings
Analyst Reiterates Buy on Apogee, Maintains $137 Price Target on Strong Zumilokibart Profile and Pipeline Upside
11d ago
APGE
Apogee Therapeutics Announces Upcoming Board Resignations, Governance Shift
Premium
Company Announcements
Apogee Therapeutics Announces Upcoming Board Resignations, Governance Shift
28d ago
8K
APGE
APGE: Best-in-Class Potential for Zumilokibart in Atopic Dermatitis Supports Undervalued Buy Rating
Premium
Ratings
APGE: Best-in-Class Potential for Zumilokibart in Atopic Dermatitis Supports Undervalued Buy Rating
2M ago
APGE
Apogee Therapeutics Prices Upsized Public Equity Offering
Premium
Company Announcements
Apogee Therapeutics Prices Upsized Public Equity Offering
2M ago
8K
APGE
Apogee Therapeutics: Strong Phase IIa IL‑13 Data Support Buy Rating and Long-Term Upside in Atopic Dermatitis
Premium
Ratings
Apogee Therapeutics: Strong Phase IIa IL‑13 Data Support Buy Rating and Long-Term Upside in Atopic Dermatitis
2M ago
APGE
APGE: Zumilokibart’s Best-in-Class Atopic Dermatitis Profile and Long-Acting Dosing Support Buy Rating and Re-Rating Potential
Premium
Ratings
APGE: Zumilokibart’s Best-in-Class Atopic Dermatitis Profile and Long-Acting Dosing Support Buy Rating and Re-Rating Potential
2M ago
APGE
More APGE News >

APGE News on the Web

CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE)
GuruFocus News
Bearish
Opaleye Management Inc. Increases Stake in Rezolute Inc.
GuruFocus News
Neutral
Opaleye Management Inc. Reduces Stake in Karyopharm Therapeutics Inc.
GuruFocus News
Neutral
Opaleye Management Inc. Reduces Stake in Harrow Inc.
GuruFocus News
Neutral
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Apogee Therapeutics (APGE)
TipRanks News
Neutral
Apogee Therapeutics (APGE) Gets a Buy from Wedbush
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Apogee Therapeutics (APGE)
TipRanks News
Neutral
Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
APGE
Sector Average
Media Buzz
This Week2 articles
Weekly Average5.75 articles
News Sentiment
This Week100%
Sector Average79%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is APGE’s Media Buzz Sentiment?
2 articles about APGE were published this week. In an average week, 5.75 articles are published.
    What is APGE’s weekly average amount of articles?
    In an average week, 5.75 articles about APGE are published.
      What is APGE’s News Sentiment?
      100% of articles about APGE were positive this week, compared to its sector average of 79%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        JUNSJupiter Neurosciences, Inc.
        Showing the stocks with the most bullish news sentiment over the past week